echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Lancet oncol: avelumab alone or combined with PLD can significantly prolong the survival prognosis of platinum-resistant/refractory ovarian cancer

    Lancet oncol: avelumab alone or combined with PLD can significantly prolong the survival prognosis of platinum-resistant/refractory ovarian cancer

    • Last Update: 2021-06-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Most patients with ovarian cancer will relapse after first-line platinum chemotherapy, and eventually develop platinum-resistant or platinum-refractory ovarian cancer
    .
    This article reports the efficacy of avelumab alone or avelumab combined with pegylated liposomal adriamycin (PLD) compared with PLD alone in patients with platinum-resistant or platinum-refractory ovarian cancer


    .


    Most patients with ovarian cancer will relapse after first-line platinum chemotherapy and eventually develop platinum-resistant or platinum-refractory ovarian cancer.


    JAVELIN Ovarian 200 is an open-label, parallel-group, three-arm, randomized phase 3 trial conducted in 149 hospitals/cancer treatment centers in 24 countries.
    It recruits 18-year-old epithelial cell ovarian cancer, fallopian tube cancer or Patients with peritoneal cancer who require no more than 3 previous treatments have an ECOG performance status of 0 or 1
    .
    The test patients were randomly divided into three groups 1:1:1, and received avelumab (10 mg/kg·2 weeks), avelumab+PLD (40 mg/m2·4 weeks) or PLD treatment, and based on their sensitivity to platinum Stratified by sex, previous anti-cancer protocols and tumor volume


    .


    Progression-free survival and overall survival

    Progression-free survival and overall survival

    From January 5, 2016 to May 16, 2017, a total of 566 patients were recruited and randomly divided into three groups: 188 in the combined group, 190 in the PLD group, and 188 in the avelumab group
    .
    As of September 19, 2018, the median follow-up times of overall survival in the combination group, PLD group and avelumab group were 18.


    4 months, 17.


    Joint group 188, PLD group of 190 people, avelumab group of 188 people with a median progression-free survival was 3.


    Treatment-related adverse events

    Treatment-related adverse events

    The most common treatment-related adverse events of grade 3 and above are palmoplantar erythema paresthesia syndrome (combination group vs PLD group vs avelumab group: vs 10% vs 5% vs 0), rash (6% vs 2% vs 0) ), fatigue (5% vs 2% vs 0), stomatitis (5% vs 3% vs 0), anemia (3% vs 5% vs 2%), neutropenia (5% vs 5% vs 0) and decreased neutrophil count (5% vs 4% vs 0)
    .
    There were 32 (18%), 19 (11%) and 14 (7%) severe treatment-related adverse events in the combination group, PLD group and avelumab group, respectively


    .


    All in all, compared with PLD alone, avelumab combined with PLD or avelumab alone can significantly prolong the progression-free survival and overall survival of platinum-resistant or refractory ovarian cancer, fallopian tube cancer, and peritoneal cancer


    Compared with PLD alone, avelumab combined with PLD or avelumab alone can significantly prolong the progression-free survival and overall survival of platinum-resistant or refractory ovarian cancer, fallopian tube cancer, and peritoneal cancer.


    Original source:

    Eric Pujade-Lauraine, et al.


    Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.